Rates and relative risk of serious adverse events in adults with polyarticular JIA and RA
| Polyarticular JIA | RA (weighted analysis) | |
|---|---|---|
| Total follow-up available (pyrs) | 3228 | 2761 |
| Mean (SD) follow-up per person (years) | 9.9 (2.5) | 8.4 (3.6) |
| Total exposure time to TNFi (years) | 1959 | 1609 |
| Mean (SD) exposure time to TNFi per person (years) | 6.1 (3.5) | 5.3 (3.5) |
| Serious infections | 42 | 37 |
| Rate (95% CI)/1000 pyrs | 23.0 (17.0 to 31.9) | 24.6 (16.9 to 37.3) |
| HR (95% CI) | 1.0 (0.6 to 1.5) | (base) |
| Disease duration-adjusted HR (95% CI) | 0.5 (0.3 to 0.9) | (base) |
| Serious cardiovascular events | 3 | 5 |
| Rate (95% CI)/1000 pyrs | 1.5 (0.5 to 7.6) | 3.0 (2.0 to 4.7) |
| HR (95% CI) | 0.5 (0.1 to 2.2) | (base) |
| Disease duration-adjusted HR (95% CI) | 0.3 (0.04 to 1.8) | (base) |
| Uveitis | 7 | 1 |
| Rate (95% CI)/1000 pyrs | 3.7 (1.8 to 8.8) | 0.7 (0.2 to 4.1) |
| HR (95% CI) | 5.1 (0.7 to 36.2) | (base) |
| Disease duration-adjusted HR (95% CI) | 4.7 (0.5 to 40.1) | (base) |
| Malignancies | 13 | 14 |
| Rate (95% CI)/1000 pyrs | 4.3 (2.5 to 7.9) | 5.5 (3.9 to 8.0) |
| HR (95% CI) | 0.8 (0.4 to 1.6) | (base) |
| Disease duration-adjusted HR (95% CI) | 0.4 (0.1 to 1.1) | (base) |
| SIR | 1.6 (0.9 to 2.9) | 1.9 (1.4 to 2.8) |
| Deaths | 14 | 16 |
| Rate (95% CI)/1000 pyrs | 4.5 (2.7 to 8.1) | 6.1 (2.7 to 16.9) |
| HR (95% CI) | 0.7 (0.4 to 1.5) | (base) |
| Disease duration-adjusted HR (95% CI) | 0.2 (0.1 to 0.6) | (base) |
| SMR | 2.2 (1.3 to 4.0) | 3.0 (1.3 to 8.2) |
HR, hazard ratio; JIA, juvenile idiopathic arthritis; pyrs, person-years; RA, rheumatoid arthritis; SIR, standardised incidence ratio; SMR, standardised mortality ratio; TNFi, tumour necrosis factor inhibitor.